Meet Floris Fauchet: From Model-Based Drug Development to Martial Arts Blog Post
You may also like AllVideo Blending Science & Impact in Drug Development: Felix Boakye-Agyeman, Vice President of the QSS Division at CertaraBlending Science & Impact in Drug Development: Felix Boakye-Agyeman,...
Transform Drug Development with Certara’s Medical Writing Expertise Blog Post
The cost of developing a single drug exceeds $2.6 billion, and the demand for life-saving treatments has never been greater. Certara is here to empower industry leaders like you to reimagine the role of medical writing in accelerating drug development timelines.
Unleashing the Power of Patents: Competitive Analysis in Material Science [Korean webinar] Blog Post
[event_date_range]
Protect Confidential Information in Investigational Drug Submissions Blog Post
Honz Slipka 2025年3月20日 Health regulatory agencies require pharmaceutical companies to protect study participants’ personal information (PI) within regulatory drug submissions. In addition, pharmaceutical organizations should avoid disclosing company-related...
Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study Blog Post
論文: The Lancet HIV Objective The IMPAACT 2017/MOCHA study, a phase 1/2 multicenter trial across five countries, assessed the safety, antiviral activity, and pharmacokinetics of long-acting injectable cabotegravir and rilpivirine... Certara & A2Healthcare accelerate Model-informed Drug Development (MIDD) adoption in Japan Blog Post
This new partnership provides Japanese biopharma companies greater access to the latest biosimulation and regulatory solutions to accelerate drug development. RADNOR, PA – 2025年3月18日 – Certara, Inc. バイオシミュレー...
Phoenix Hosted: Cloud-Based PK/PD Software for Smarter, Faster Research Blog Post
In this on demand webinar, you’ll discover why Phoenix Hosted is the ideal solution for R&D companies of all sizes.
